MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Trastuzumab Rezetecan

Search medical newsFind research, conditions and clinical updates
  • Home
  • Trastuzumab Rezetecan
Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels
Posted innews Oncology Otorhinolaryngology

Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels

Posted by By MedXY 08/14/2026
This phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Advancing Post-Stroke Upper Limb Assessment: The FULMA Single-Camera Markerless Motion Capture System
  • Evaluating the 0/1-Hour Cardiac Troponin Pathway: Safety Confirmed but No Reduction in Emergency Department Stay
  • Enhancing Adolescent STI Screening: A Multisite Primary Care Quality Improvement Initiative for Chlamydia and Gonorrhea
  • Differential Impact of Disease Activity on Bone Quality in Rheumatoid and Psoriatic Arthritis: A 7-Year Longitudinal HR-pQCT Study
  • Assessing Center-Level Variability in Clinical Data Updates for US Lung Transplant Candidates: Implications for Allocation Equity
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top